Migraine Headache Clinical Trial
Official title:
Intranasal Evaporative COOLing for the Symptomatic Relief of Migraine HEADache - A Randomized, Double Blind, Placebo Controlled Study"
This study will be a randomised placebo controlled trial examining the effectiveness of using an intranasal cooling device (the RhinoChill) in providing relief of pain and symptoms of acute migraine. It will involve using two nasal catheters to cool the nasal cavity which provides localised cooling of the local nasal tissue and the blood vessels which supply blood to the brain. This cooling effect will cause the blood vessels to constrict as well as stimulating special cold receptors that are thought to be involved in the relief of migraine, thereby providing both pain and associated symptomatic relief. Ninety patients will be randomised in a 1:1 fashion, clustered to three different recruitment sites. The patients will have a 30 day period of data collection for their current migraine frequency, treatment and response to medication (with a minimum of 2 migraine attacks recorded) before starting the treatment phase with the RhinoChill Device. Treatment will be for 2 migraine attacks. Only a single treatment is allowed for the first attack, but on the second attack the patient may deliver 2 treatments with a gap of at least 2 hours between treatments.
This study is a multi centre, double blinded, randomized, prospective, parallel placebo
controlled trial for demonstrating the effectiveness of the RhinoChill System for the
symptomatic relief of migraine headache.
The specific study design consists of:
- Participant identification from neurology clinic records and gaining initial consent to
transfer contact details to the trial team.
- Telephone contact or direct clinic contact with potential participants to describe the
COOLHEAD 2 trial and to seek expressions of interest.
- Initial meetings with potential participants and discussion of trial, provision of
patient information leaflets. Informed Consent taking.
- Initial 30 day prospective data collection period (minimum of 2 migraine attacks,
longer period if needed)
- Randomisation to either placebo or active RhinoChill
- Device Delivery and training session for the use of the RhinoChill device, self
administration, and record keeping.
- Treatment period for the treatment of 2 separate migraines with the RhinoChill.
During an initial screening visit or phonecall, the trial will be discussed with the
potential participant and the inclusion/exclusion checklist will be completed.
If the patient meets all inclusion criteria and none of the exclusion criteria, they will be
asked for permission to pass on contact details to a member of the trial team for further
contact.
Arrangements will then be made for a meeting with the patient either at the clinic or in
their own home to further discuss the trial and to consider enrolling into the study. At
this time, they will be provided with a patient information sheet and will be shown the
RhinoChill device. The patient will be given the opportunity to fully consider all aspects
of participation in this trial and to discuss it with family members if they so wish before
being being consented into the trial by a member of the study team.
At the time of consent, the researcher will also collect data for the baseline CRF and
provide initial instruction on completion of the first stage data collection forms (further
described below)
At the baseline visit, the patient will first be given the opportunity to ask any questions
they may have about the research. A member of the research team will take informed consent
and gain signatures on the consent form. Baseline data will then be collected, including
history of migraine headache, frequency, severity of symptoms, medication and therapies
currently ongoing or taken in the past. Base line vital signs will also be recorded at this
time. Once completed, a short training session on completion of the prospective data
collection forms for phase 1 of the trial will given and use of the supplied blood pressure
machine and pulse oxymeter machine. Once the baseline visit has been completed the patient
will begin a 30 day period of self data collection based on their migraine experience during
that time frame and using data capture forms provided by the research nurse (a minimum of 2
migraine attacks are required, therefore if 2 have not occurred during the 30 days, further
time will be given to allow the second migraine to occur).
If a patient has not had a single migraine in the first 30 days, then they will not be able
to continue to the treatment phase as they have not met the inclusion criteria of at least 1
migraine per month. Following the conclusion to this initial period, the treatment phase
will then begin.
After the end of the prospective data collection period, the patient will be randomised to
either active treatment or placebo treatment. Randomisation will be provided by sealed
envelopes held by E&E CRO services (Vienna) who are also acting as independent monitors of
the trial. Randomisation was performed via the online system www.sealedenvelope.com.
Training will be undertaken to ensure that the patient is fully competent and safe in the
use of the RhinoChill intranasal cooling device.
The patient will be instructed on:
- Preparation of the device
- Insertion of the nasal catheter
- Selecting correct flow rate
- Positioning during treatment
- Cleaning and storage of the nasal catheters
- Trial documentation
- 24 hour contact numbers for additional supplies, troubleshooting and practical support.
The patient will also be left with a reference booklet for issues around the trial and the
practical use of the RhinoChill device.
At the onset of migraine headache (or as soon as possible thereafter), the patient will
start to complete the 'Treatment' CRF.
Each step of the treatment procedure is to be completed in order and as described to the
patient. Patients are instructed that there is no scope for any alteration in the treatment
order or requirements of the trial unless a safety issue becomes evident. If a patient does
deviate from the standard procedures as outlined below, they are required to contact the 24
hour COOLHEAD 2 mobile phone to report the incident so that it can be reviewed and logged as
a protocol deviation and reviewed by the site/principal investigator at the earliest
opportunity. The RhinoChill device is then prepared for use and treatment can be
administered.
The RhinoChill Migraine Intranasal catheters are then inserted and the 10 minute treatment
is commenced on Low Flow. following these steps for each individual treatment:
It is recognised that participants in this study will already be taking medication for their
migraine headache. Normal prophylaxis will be allowed as part of the trial and will be
recorded in the initial screening interview. No change in prophylaxis is allowed within
three months of the start of the trial or while the patient is participating in the trial.
However, acute treatments such as triptans are allowed to be taken but must be withheld
until at least two hours following completion of treatment with the RhinoChill to allow
assessment of the intervention. Any rescue medication taken after this point will be
recorded in the associated trial documentation. A full medication history along with other
therapies (including alternative therapies) will also be recorded.
No new treatment or therapy will start while the participant is enrolled in this trial.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Not yet recruiting |
NCT05943457 -
Vitamin K2 Supplementation in Adult Episodic Migraine
|
N/A | |
Completed |
NCT01211145 -
Zomig - Treatment of Acute Migraine Headache in Adolescents
|
Phase 4 | |
Completed |
NCT00530517 -
A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack
|
Phase 2 | |
Completed |
NCT00898677 -
Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)
|
Phase 3 | |
Recruiting |
NCT06459635 -
Migraine Attack Pain Phase Prediction Study
|
||
Completed |
NCT03971071 -
A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
|
Phase 4 | |
Withdrawn |
NCT02706015 -
Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks
|
Phase 3 | |
Completed |
NCT02518464 -
Ticagrelor Therapy for RefrACTORy Migraine Study
|
Phase 4 | |
Terminated |
NCT00391755 -
A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches
|
Phase 4 | |
Completed |
NCT03401346 -
Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults
|
Phase 1 | |
Completed |
NCT05085483 -
Ketone for Migraine Prevention
|
N/A | |
Completed |
NCT01604785 -
Low-dose Propofol for Pediatric Migraine
|
Phase 2/Phase 3 | |
Terminated |
NCT00804973 -
Study in Participants With Acute Migraines Headaches
|
Phase 2 | |
Completed |
NCT03341689 -
Psilocybin for the Treatment of Migraine Headache
|
Phase 1 | |
Completed |
NCT01630044 -
Neurostimulation Device for Treatment of Migraine Headache
|
N/A | |
Active, not recruiting |
NCT00285402 -
Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine
|
Phase 2 | |
Completed |
NCT00203255 -
Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache
|
N/A | |
Recruiting |
NCT06046508 -
Migraine With Aura and Patent Foramen Ovale: Identification of Biomarkers to Select Patients In Whom Intervention Would Be Beneficial (MANET)
|
||
Active, not recruiting |
NCT04584762 -
Automated Variable Pattern Insufflator Device (AVPI) for the Acute Treatment of Migraine
|
N/A |